Radar · Life Sciences in Auvergne Rhone Alpes
Best Life Sciences Companies in Auvergne Rhone Alpes, France
The 194 best Life Sciences companies in Auvergne Rhone Alpes, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Amolyt Pharma.
By Rohit KhannaTrends & Stories
194companies tracked
$1.7Bdisclosed funding
0unicorns
85have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × AUVERGNE RHONE ALPES
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
62%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2015median founding year
341kcombined LinkedIn audience
37%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Auvergne Rhone Alpes
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Amolyt Pharma Developer of peptide therapeutics to treat rare endocrine and metabolic disorders | $292M | 41 mo ago | Acquired | 6 | 2015 | — | — | — |
| 2 | Valneva Developer of prophylactic vaccines for infectious diseases | $144M | 44 mo ago | Public | 719 | 1999 | WordPressMySQLPHP+24 | 195 patents Viral vaccine production and subunit vaccine formulation for chikungunya and respiratory pathogens | — |
| 3 | eCential Robotics Developer of robotic surgery platform combining imaging, navigation, and robotic assistance | $133M | 65 mo ago | Series C | 132 | 2009 | Craft CMSPHPUbuntu+11 | 115 patents Image-guided surgical robotics for orthopedic procedures with real-time tracking and planning | — |
| 4 | Diabeloop Developer of automated and personalized systems for type 1 diabetes 72Innovation top 15%Patents top 20%AI top 20%Moat top 21% All 11 signals ▾Innovationtop 15% Patentstop 20% AItop 20% Moattop 21% Fundingtop 31% Growthtop 45% Talentbottom 49% Marketbottom 47% Techbottom 47% Globalbottom 42% Newsbottom 27% Innovation: 65 patents (top 15% of patent-holders) · 57 filings since 2022 vs 8 in 2017-21 Patents: 65 patents matched (strict assignee match) · 57 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $124M | 48 mo ago | Series C | 158 | 2015 | WordPressApple iCloud MailGoogle Workspace+19 | 65 patents Closed-loop glucose monitoring and insulin dosing algorithms for diabetes management | 3 launchs · 1 partnership |
| 5 | Enyo Pharma Developer of therapeutics for diseases with impaired kidney function 60Patents top 20%Innovation top 21%Funding top 25%Moat top 26% All 9 signals ▾Patentstop 20% Innovationtop 21% Fundingtop 25% Moattop 26% Growthtop 45% Techbottom 49% Globalbottom 43% Marketbottom 40% Newsbottom 27% Patents: 164 patents matched (strict assignee match) · 114 filings since 2022 vs 50 in 2017-21 Innovation: 164 patents (top 16% of patent-holders) · 114 filings since 2022 vs 50 in 2017-21 rank vs industry peers · Fliar Intelligence Index 60/100 | $113M | 12 mo ago | Series C | 34 | 2014 | WordPress Block EditorWordPressMySQL+18 | 164 patents Novel antiviral small‑molecule salts and FXR‑agonist combos for hepatitis D therapy | — |
| 6 | UroMems Developer of active implantable devices for urological incontinence 72Funding top 21%Tech top 25%Patents top 27%Innovation top 28% All 9 signals ▾Fundingtop 21% Techtop 25% Patentstop 27% Innovationtop 28% Moattop 29% Growthtop 35% Globalbottom 43% Marketbottom 42% Newsbottom 22% Funding: Raised $85.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Tech: 33 technologies across 5/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 72/100 | $86M | 1 mo ago | Series D | 49 | 2011 | WordPressMySQLPHP+21 | 173 patents Implantable occlusive devices and control systems for sealing anatomical ducts and protecting sensors | 3 job openings · 1 internship |
| 7 | Biom'Up Developer of hemostatic products for surgical applications | $84M | 82 mo ago | Public | 104 | 2005 | — | 59 patents Hemostatic powders and collagen-based wound sealing devices for surgical bleeding control | — |
| 8 | Inova Cloud-based biopharma CRM and CRO collaborating system for the life science industry | $71M | 59 mo ago | Series C | 137 | 2010 | — | 5 patents Heat‑resistant culinary apparel with elastic closures for improved chef comfort | — |
| 9 | PDC*line Pharma Developer of therapeutic vaccines for the treatment of cancer | $65M | 54 mo ago | Series B | 34 | 2014 | DrupalPHPGoogle Maps+13 | — | — |
| 10 | Advanced Accelerator Applications Novartis company, developing molecular nuclear medicine theranostics | $56M | 134 mo ago | Acquired | 1,038 | 2002 | DrupalPHPVideoJS+16 | 215 patents Formulating stable, concentrated radiopharmaceutical complexes for diagnostic and therapeutic use. | — |
| 11 | EYE TECH CARE Developer of ultrasound device to treat glaucoma | $52M | 45 mo ago | Series D | 19 | 2008 | TYPO3 CMSPHPBootstrap+7 | 111 patents Patents concentrated in health & consumer products | — |
| 12 | Poxel Developer of therapeutic solutions for the treatment of Type 2 diabetes | $50M | 46 mo ago | Public | 37 | 2009 | BootstrapApache HTTP ServerjQuery+7 | 338 patents Deuterated small‑molecule drugs targeting metabolic, neurological and rare genetic disorders. | — |
| 13 | MaaT Pharma Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42M | 59 mo ago | Public | 71 | 2014 | WordPressMySQLPHP+25 | 171 patents Patents concentrated in health & consumer products | 1 internship |
| 14 | Kayentis Provider of electronic clinical outcome assessment solutions for clinical trials | $36M | 38 mo ago | Series D | 12 | 2003 | WordPressMySQLPHP+25 | — | 2 job openings · 2 launchs |
| 15 | Mablink Provider of Antibody-Drug-Conjugates (ADC's) technology for cancer treatment | $35M | 44 mo ago | Acquired | 29 | 2018 | — | — | — |
| 16 | Osivax Developer of vaccines against constantly mutating pathogens 32Growth top 28%Funding top 37%Moat top 37%Patents top 40% All 10 signals ▾Growthtop 28% Fundingtop 37% Moattop 37% Patentstop 40% Innovationtop 49% Globalbottom 45% Techbottom 37% Marketbottom 33% Newsbottom 21% Fin. healthbottom 15% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $31.8M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $32M | 15 mo ago | Series B | 40 | 2017 | WordPressMySQLPHP+24 | 16 patents mRNA and protein-based vaccine formulation and delivery technologies | 1 job opening |
| 17 | Keranova Surgical equipment for anterior chamber Ophthalmic surgery | $31M | 81 mo ago | Series B | 46 | 2015 | WordPressMySQLPHP+18 | 146 patents Ophthalmic laser cutting systems with optical coupling and bubble-energy optimization | — |
| 18 | Remedee Labs Developer of endorphin stimulation therapy for pain management | $28M | 42 mo ago | Series A | 39 | 2016 | WordPressMySQLPHP+21 | 36 patents Wearable millimeter-wave antenna devices for therapeutic and cosmetic electromagnetic treatment | — |
| 19 | Adocia Developer of therapeutics for the treatment of diabetes and obesity 45Product top 14%Patents top 28%Innovation top 35%Funding top 35% All 11 signals ▾Producttop 14% Patentstop 28% Innovationtop 35% Fundingtop 35% Moattop 35% Markettop 49% Growthbottom 47% Techbottom 45% Globalbottom 43% Fin. healthbottom 35% Newsbottom 30% Product: 5 distinct product lines · Company stage: Public Patents: 684 patents matched (strict assignee match) · 119 filings since 2022 vs 272 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $26M | 6 mo ago | Public | 111 | 2005 | WordPressApple iCloud MailMicrosoft 365+23 | 684 patents Peptide therapeutics formulation and delivery using polymer conjugates and injectable hydrogels | — |
| 20 | Brenus Pharma Developer of immunotherapy for the treatment of cancer | $25M | 21 mo ago | Series A | 12 | 2020 | WordPressMySQLPHP+12 | — | — |
| 21 | Cytoo Specializes in the development of physiologically-relevant cellular models and assays for High Content… | $16M | 174 mo ago | Series C | 36 | 2008 | WordPressMySQLPHP+21 | 39 patents Therapeutics and AI-driven assays for skeletal muscle hypertrophy and disease diagnostics | — |
| 22 | NH TherAguix Developer of nanoparticle-based theranostic for the treatment of cancer | $16M | 86 mo ago | Series A | 18 | 2015 | — | 94 patents Nanoparticle-based drug delivery and radiopharmaceutical imaging/therapy | — |
| 23 | Surgivisio Imaging and computer-assisted minimally invasive surgery | $14M | 98 mo ago | Series B | 222 | 2009 | — | 44 patents Image-guided surgical navigation and robotic assistance for minimally invasive orthopedic procedures | — |
| 24 | Healshape Developer of products for breast reconstruction and augmentation | $13M | 47 mo ago | Series A | 9 | 2020 | WordPressMySQLPHP+17 | 6 patents 3D-printed medical implants for customized anatomical reconstruction | — |
| 25 | GenOway Provider of transgenic rodent models and customized cell lines for preclinical development | $12M | 77 mo ago | Public | 124 | 1999 | WebflowMatomo AnalyticsGoogle Analytics+16 | 15 patents Genetically engineered animal models with conditional KO/KI and advanced cloning vectors | 1 partnership |
| 26 | NETRI Developer of microfluidic devices for industrial applications | $9M | 16 mo ago | Series A | 45 | 2018 | WordPressMySQLPHP+34 | 33 patents Microfluidic cell‑culture platforms integrating humidification and large‑scale neural activity assays | 2 partnerships |
| 27 | Netris pharma Developer of therapeutic solutions to treat cancer | $8M | 30 mo ago | Series A | 14 | 2008 | WordPressPleskMySQL+20 | 120 patents Patents concentrated in chemistry & materials | — |
| 28 | Tollys Developer of drugs for treating cancer | $7M | 71 mo ago | Series A | 11 | 2015 | — | 10 patents TLR3 agonist immunomodulators for epithelial and myeloid cell activation in therapeutics | — |
| 29 | Fabentech Developing polyclonal antibodies to treat infectious diseases such as avian influenza, ebola etc. | $7M | 42 mo ago | Series A | 54 | 2009 | WordPressMySQLPHP+5 | 6 patents Recombinant antibody production for passive immunotherapy against H5N1 influenza | — |
| 30 | Ciliatech Developer of a implant for treating ophthalmic disorder | $7M | 37 mo ago | Series A | 2 | 2017 | — | 19 patents Ocular interposition implants with surface projections for enhanced fixation and positioning | 1 job opening |
| 31 | Blink Biomedical Antibody-based checkpoint inhibitors for oncology. | $6M | 119 mo ago | Series A | 11 | 2015 | — | 25 patents Therapeutic antibodies for nicotine addiction and CD96-mediated immune modulation | — |
| 32 | 3-D Matrix Developer of synthetic peptides for medical applications | $6M | 18 mo ago | Public | 37 | 2004 | HubSpot CMS HubMaterial Design LiteMicrosoft Clarity+14 | 23 patents Patents concentrated in health & consumer products | — |
| 33 | In2Bones Provider of single use surgical instruments and orthopedic implants for use in lower extremity surgeries. | $6M | 103 mo ago | Acquired | 62 | 2011 | — | 93 patents Orthopedic tibial and ankle joint replacement implants and surgical instrumentation | 1 launch |
| 34 | Signia Therapeutics Re-purposed formulations for influenza infections | $5M | 48 mo ago | Deadpooled | 8 | 2017 | — | 15 patents Repurposed diltiazem-based antiviral combinations for SARS‑CoV‑2 treatment | — |
| 35 | Axess Vision Technology Products for video-Bronchoscopy, video-Ureteroscopy and video-Cystoscopy | $5M | 150 mo ago | Acqui-Hired | 40 | 2006 | — | 138 patents Advanced control and sterilization mechanisms for flexible medical endoscopes. | 1 partnership |
| 36 | ErVimmune Developer of immunotherapies for the treatment of cancer 16News top 36%Moat top 38%Funding top 40%Patents top 44% All 9 signals ▾Newstop 36% Moattop 38% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 36% Marketbottom 25% Techbottom 23% News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 16/100 | $5M | 4 mo ago | Series A | — | 2019 | WordPressApple iCloud MailMicrosoft 365+16 | 9 patents HERV-based cancer epitope discovery and AML diagnostic/therapeutic biomarkers | 1 job opening |
| 37 | Trixell Manufacturer of X-ray digital detectors imaging plates for radiological imaging industry | $5M | 77 mo ago | Funding Raised | 192 | 1997 | DrupalPHPBootstrap+6 | 320 patents High‑performance matrix detectors for ionizing radiation imaging, especially low‑dark‑current medical scanners. | — |
| 38 | Sublimed Developer of pain management devices | $5M | 89 mo ago | Series A | 22 | 2015 | WordPressMySQLPHP+18 | 2 patents Implantable neurostimulation therapy for chronic knee osteoarthritis pain relief | — |
| 39 | Electroducer Developer of devices for coronary interventions and direct wire pacing | $4M | 59 mo ago | Series A | — | 2018 | — | 37 patents Intravascular catheters for cardiac diagnostics, valve replacement, and autonomic nerve stimulation. | — |
| 40 | NeoMedLight Fiber-optic phototherapy device for neonatal care | $3M | 61 mo ago | Series A | 10 | 2014 | WordPressMySQLPHP+22 | 9 patents Wearable textile phototherapy devices integrating light applicators for targeted skin treatment | — |
| 41 | Allogenica Biotechnology company specializing in the development of allogeneic CAR-T therapies for cancer treatment | $3M | 15 mo ago | Funding Raised | — | 2022 | WixSentryApple iCloud Mail+13 | — | — |
| 42 | Elsalys Biotech Develops therapeutic monoclonal antibodies for cancer and inflammatory diseases | $3M | 65 mo ago | Acqui-Hired | 14 | 2013 | — | 17 patents Immunotherapeutic agents targeting CD160 and TYRO3 receptors for disease treatment | — |
| 43 | Laclarée Developer of an eye-wear solution for presbyopia correction | $2M | 16 mo ago | Seed | 10 | 2016 | WordPressApple iCloud MailMySQL+22 | — | — |
| 44 | Hunt X Pharma Developer of therapeutics for neurological diseases | $2M | 21 mo ago | Seed | — | 2022 | — | — | — |
| 45 | StromaCare Developer of immunotherapy for the treatment of solid tumors | $2M | 48 mo ago | Seed | 9 | 2020 | — | — | — |
| 46 | CTIBiotech Develops 3D human tissue models 19Tech top 45%Talent bottom 49%Funding bottom 47%Global bottom 29% All 5 signals ▾Techtop 45% Talentbottom 49% Fundingbottom 47% Globalbottom 29% Marketbottom 25% Tech: 17 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 19/100 | $1M | 1 mo ago | Funding Raised | — | 2009 | Hostinger Website BuilderNginxOpenResty+14 | — | 2 launchs · 1 partnership · 1 award |
| 47 | Meddenovo Developer of computational biochemistry software for pharmaceutical research and development | $1M | 22 mo ago | Seed | — | 2021 | — | — | — |
| 48 | Smartox Biotechnology Discovery and the synthesis of peptides coming from animal venoms and related drug discovery services | $1M | 32 mo ago | Seed | 14 | 2009 | Cart FunctionalityWooCommerceWordPress+23 | — | — |
| 49 | Nemera Manufacturer of Plastic drug delivery devices for multiple specialties | $849K | 10 mo ago | Acquired | 455 | 2014 | WordPress Block EditorWordPressMySQL+28 | — | 2 launchs |
| 50 | TheraPPI Biotech company developing protein interaction solutions for cancer and related diseases | $113K | 14 mo ago | Seed | — | 2023 | — | — | — |
Top 12 Life Sciences companies in Auvergne Rhone Alpes
#1
Series D · Grenoble, Auvergne Rhone Alpes · founded 2011 · 49 employees$85.7Mraised▾
Series D · Grenoble, Auvergne Rhone Alpes · founded 2011 · 49 employees
Developer of active implantable devices for urological incontinence. The device MyoElectroMechanical System is based on a technology where a patient‘s activity is measured in real-time through micro-sensors inside the implant into which algorithms are embedded; the system interprets data coming from the micro-sensors and computes the urethral pressure to apply.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 21%Tech
top 25%Patents
top 27%Innovation
top 28%Moat
top 29%Growth
top 35%Funding: Raised $85.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) · Last round Series D (May 2026)
Tech: 33 technologies across 5/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Patents: 173 patents matched (strict assignee match) · 78 filings since 2022 vs 69 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 10k LinkedIn followers — 3.0% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Antené(e) de Recherche Clinique Senior, Engineering Director Medical Device
Funding rounds
- May 2026Series D$60M
- Jun 2024Series C$47M
- Apr 2021Series B$8.3M
- May 2020Series B$17.5M
Investors
Financiere Arbevel, Wellington Partners Venture Capital, Bpifrance, Supernova Invest, b2venture, CITA
Tech stack
CloudflareCloudflare Bot ManagementComplianzCore-JsElementorGenesis Blocks
#2
Public · Lyon, Auvergne Rhone Alpes · founded 2005 · 111 employees$26Mraised▾
Public · Lyon, Auvergne Rhone Alpes · founded 2005 · 111 employees
Developer of therapeutics for the treatment of diabetes and obesity. Its proprietary platform called the 'Biochaperone' enhances the effectiveness and safety of therapeutic proteins and enables easier usage on patients. Their clinical pipeline includes a unique formulation of PGDF-BB for the treatment of diabetic foot ulcers and insulin formulations for the treatment of diabetes.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Patents
top 28%Innovation
top 35%Funding
top 35%Moat
top 35%Market
top 49%Product: 5 distinct product lines · Company stage: Public
Patents: 684 patents matched (strict assignee match) · 119 filings since 2022 vs 272 in 2017-21 · Latest publication 2026
Innovation: 684 patents (top 4% of patent-holders) · 119 filings since 2022 vs 272 in 2017-21 · 5 product lines
Audience (LinkedIn): 13k LinkedIn followers — 3.8% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$11.7M
- Feb 2025Post IPO$10.2M
- Oct 2019Conventional Debt$16.5M
- Jan 2010Series B$14M
Investors
Bioam, Idinvest Partners, Smalt Capital, CDC Enterprises, IPF Partners, Stifel
Tech stack
All In One SeoApache Http ServerApple Icloud MailBootstrapComplianzContact Form 7
#3
Series C · Lyon, Auvergne Rhone Alpes · founded 2014 · 34 employees$113.5Mraised▾
Series C · Lyon, Auvergne Rhone Alpes · founded 2014 · 34 employees
Developer of therapeutics for diseases with impaired kidney function. The company offers VONAFEXOR is a small molecule with strong fibrolytic and anti-inflammatory properties in both organs, kidney and liver.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Patents
top 20%Innovation
top 21%Funding
top 25%Moat
top 26%Growth
top 45%Tech
bottom 49%Patents: 164 patents matched (strict assignee match) · 114 filings since 2022 vs 50 in 2017-21 · Latest publication 2026
Innovation: 164 patents (top 16% of patent-holders) · 114 filings since 2022 vs 50 in 2017-21
Funding: Raised $113M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Series C (Jun 2025)
Audience (LinkedIn): 9k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- Jun 2025Series C$6.9M
- Jan 2024Series C$42.8M
- Oct 2018Grant (prize money)$2.8M
- Jun 2018Series B$46.6M
Investors
Sofinnova Partners, Bpifrance, Morningside, Europa, Orbimed, Andera Partners
Tech stack
BootstrapCloudflareCloudflare Bot ManagementEnyoFont AwesomeGoogle Analytics
#4
Series A · Lyon, Auvergne Rhone Alpes · founded 2019$4.8Mraised▾
Series A · Lyon, Auvergne Rhone Alpes · founded 2019
Developer of immunotherapies for the treatment of cancer. The company combines cancer vaccines and T-cell therapies to create treatments based on the identification of new families of tumor antigens.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
News
top 36%Moat
top 38%Funding
top 40%Patents
top 44%Talent
bottom 49%Innovation
bottom 48%News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding
Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents
Funding: Raised $4.8M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (Jan 2026)
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Bioinformatics Engineers, Data Scientists – Immuno-Oncology
Funding rounds
- Jan 2026Series A$19.8M
- Jun 2023Grant (prize money)$15.4M
- Jan 2023Seed$4.8M
Founders & team
Investors
EIC Fund, Seventure Partners, Bpifrance, SPRIM Global Investments
Tech stack
Apple Icloud MailComplianzDiviFont AwesomeGoogle Font ApiJquery
#5
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2009$1.5Mraised▾
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2009
CTIBiotech is a developer of 3D human tissue models for the pharmaceutical industry and dermato-cosmetics sectors. The company also claims of printing cancer tissues in 3D using the tools in bioengineering. It offers 3D tissue and cell models to the pharmaceutical industry for cancer research, regenerative medicine, medical devices, public and private research institutions, and organizations. Offers human biological sample procurement & cell harvesting.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Tech
top 45%Talent
bottom 49%Funding
bottom 47%Global
bottom 29%Market
bottom 25%Tech: 17 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services · Devops: Nginx
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding: Raised $1.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Grant (prize money) (Apr 2026)
Audience (LinkedIn): 8k LinkedIn followers — 2.3% of this cohort's audience
Activity (LinkedIn): 2 product launches · 1 partnerships · 1 awards (incl. KOSÉ Corporation) announced in 12 mo
Funding rounds
- Apr 2026Grant (prize money)$1.5M
Founders & team
Investors
Bpifrance, Government of France
#6
Series B · Lyon, Auvergne Rhone Alpes · founded 2017 · 40 employees$31.8Mraised▾
Series B · Lyon, Auvergne Rhone Alpes · founded 2017 · 40 employees
Developer of vaccines against constantly mutating pathogens. The company leverages oligoDOM a novel proprietary nanoparticles technology specifically designed to trigger superior T-cell responses. The company's lead candidate is OVX836 against influenza and coronavirus.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 28%Funding
top 37%Moat
top 37%Patents
top 40%Innovation
top 49%Global
bottom 45%Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $31.8M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) · Last round Series B (Mar 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 16 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers — 2.4% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Chargé(e) de Biochimie analytique, Chargé(e) de Purification des Protéines
Activity (LinkedIn): 1 partnerships (incl. CEPI) announced in 12 mo
Funding rounds
- Mar 2025Series B$10.5M
- Dec 2023Grant (prize money)—
- Mar 2023Grant (prize money)$1M
- Jun 2022Grant (prize money)$10.5M
Investors
Noshaq, Anaxago, Bpifrance, NIAID, Gates, EIC Fund
Tech stack
Contact Form 7CookieyesCore-JsElementorEssential Addons For ElementorFont Awesome
#7
Series A · Issoire, Auvergne Rhone Alpes · founded 2020 · 12 employees$25Mraised▾
Series A · Issoire, Auvergne Rhone Alpes · founded 2020 · 12 employees
Developer of immunotherapy for the treatment of cancer. The company's flagship product includes STC-1010 which is used to treat metastatic colorectal cancer (mCRC) and solid cancers.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers
Funding rounds
- Sep 2024Series A$25M
Founders & team
Investors
UI Investissement, Credit Agricole, Noshaq, Investsud, Capitaletcroissance.be
#8
Series A · Lyon, Auvergne Rhone Alpes · founded 2018 · 45 employees$8.9Mraised▾
Series A · Lyon, Auvergne Rhone Alpes · founded 2018 · 45 employees
Developer of microfluidic devices for industrial applications. The company has NeoBento a microfluidic platform that focuses on the development of next-generation 3D brain-on-a-chip models for the treatment of neurological diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers — 3.2% of this cohort's audience
Activity: 2 partnerships (incl. NAMs IAMPS and Japan) announced in 12 mo
Funding rounds
- Feb 2025Series A$5.1M
- Mar 2022Series A$8.9M
Founders & team
Investors
Polygone, NetAngels, Neovacs, Bpifrance, Altana Investissements
Tech stack
All In One SeoApache Http ServerBootstrapCloudflareCloudflare Bot ManagementComplianz
#9
Acquired · Ecully, Auvergne Rhone Alpes · founded 2015 · 6 employees$292.3Mraised▾
Acquired · Ecully, Auvergne Rhone Alpes · founded 2015 · 6 employees
Developer of peptide therapeutics to treat rare endocrine and metabolic disorders. The pipelineincludes two therapeutic peptide programs eneboparatide for the treatment of hypoparathyroidism and AZP-3813 for the treatment of acromegaly.
Funding rounds
- Jan 2023Series C$137.5M
- Sep 2021Series B$80M
- Aug 2019Series A$74.8M
Investors
Sectoral, Andera Partners, ATEM Capital, Life Sciences Partners, Mass General Brigham Ventures, Orbimed
#10
Public · Caluire et Cuire, Auvergne Rhone Alpes · founded 2004 · 37 employees$5.9Mraised▾
Public · Caluire et Cuire, Auvergne Rhone Alpes · founded 2004 · 37 employees
3-D Matrix develops synthetic peptides for medical applications. The company synthesizes the self-assembling peptide matrix which is composed of three amino acids in a sequence that is repeated 4 times (Arginine - Alanine - Aspartic Acid - Alanine). The company's product includes PuraStat, a self-assembling synthetic peptide scaffold that mimics the human extra cellular matrix (ECM). The product is used in endoscopic, cardiac, and ENT solutions.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Nov 2024Post IPO$5.7M
- Jan 2021Grant (prize money)$231.9K
Investors
Europa
Tech stack
CloudflareCloudflare Bot ManagementCore-JsFlickityGodaddyGoogle Analytics
#11
Acquired · La Verpilliere, Auvergne Rhone Alpes · founded 2014 · 455 employees$848.9Kraised▾
Acquired · La Verpilliere, Auvergne Rhone Alpes · founded 2014 · 455 employees
Nemera is a Manufacturer of Plastic drug delivery devices for multiple specialties. Montagu Private Equity acquired Centor and Nemera from Rexam PLC in a combined transaction in May 2014 through a management buyout. After the acquisition, Montagu renamed the former Rexam prescription retail unit Centor and the Rexam healthcare devices unit. Nemera's products include Ophthalmic (preservative-free multidose eyedroppers), Ear, Nose, Throat (sprays/ pumps, etc.), Inhalation (pMDI, MDIs, DPIs), Dermal and Transdermal (airless & atmospheric dispensers), and Parenteral (auto-injectors, pens, safety devices & implanters) drug delivery devices. Some of its flagship brands are Advancia, Inhalia, Safe’n’Sound and Novelia
LinkedIn Pulse recent public activity · Jul 2026
Audience: 49k LinkedIn followers — 14.5% of this cohort's audience
Activity: 2 product launches announced in 12 mo
Funding rounds
- Aug 2025Seed—
- Feb 2017Grant (prize money)$430.6K
- Jan 2017Grant (prize money)$418.3K
Investors
Europa, LGT Capital Partners, ATP Private Equity Partners, Omnes Capital
Tech stack
BootstrapCdnjsCloudflareComplianzDocusignGoogle Analytics
#12
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2022$2.7Mraised▾
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2022
Biotechnology company specializing in the development of allogeneic CAR-T therapies for cancer treatment. It uses healthy donor hematopoietic stem cells as the starting material, rather than the patient's own T cells. Company stem cells are bioengineered to express the CAR and then differentiated into immature precursor T cells called CAR-pre-T cells.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$2.7M
Founders & team
Investors
Diplomatie
Tech stack
Apple Icloud MailBootstrapGoogle CloudGoogle Cloud CdnGsapHsts
Funding & investor landscape
$1.7Btotal disclosed funding
79companies funded
211disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Stephane Depil
Founder · ErVimmune
Nico Forraz
CEO · CTIBiotech
Jacques Gardette
CEO · Brenus Pharma
Florian Larramendy
CEO - CTO - Co-founder · NETRI
Thibault Honegger
Co-Founder & CEO · NETRI
Inna Menkova
Co-Founder & CEO · Allogenica
Thomas Lingelbach
President & CEO · Valneva
Bruno Berge
Founder & CEO · Laclarée
Erik Huneker
Co-Founder · Diabeloop
Philippe Berna
Founder · Kayentis
Thomas Kuhn
Co-Founder & CEO · Poxel
Sebastien Bolze
Co-Founder · Poxel
Prism market signals · France · country-scoped Prism corpus, 2,021,151 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · France
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
research sentiment over time
200820152026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 38% → 41% across 2008–2026.
top research entities
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
leading researchers
Pauline Le Boulch · Anani Amegan Missinou · Stéphanie Boutet · François Perreau · Maria J. Manzanares-Dauleux · Martin Beaumont · Jordi Estellé · Sofia Titah
▲
Breakthroughs337 · 28%
▼ 31%→27% share
▼0.9× share momentum0 median citations80% since 2021mostly empirical
Gene-focused breakthrough research surged from 3 to 26 papers, with virus and transcription factor topics newly emerging.
rising sub-themes (early→recent)
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
Newly emergingVirus 0→9 · Transcription factor 0→8 · Bacteria 0→7
Landmark Targeting DNA Double-Strand Breaks with TAL Effector Nucleases · 1,987 cites
◆
Advancements418 · 34%
▲ 31%→36% share
▲1.2× share momentum0 median citations86% since 2021mostly empirical
Advancements field-share rose 31%→36%; transcriptome, metabolomics, and microbiome all newly emerged alongside gene papers tripling to 30.
rising sub-themes (early→recent)
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
Newly emergingTranscriptome 0→13 · Metabolomics 0→12 · Microbiome 0→12
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns221 · 18%
▼ 25%→16% share
▼0.6× share momentum0 median citations74% since 2021mostly empirical
Antibiotic resistance concern papers nearly quadrupled 3→12; drug resistance and food security newly flagged as concerns.
rising sub-themes (early→recent)
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Newly emergingFood security 0→8 · Selection (genetic algorithm) 0→8 · Drug resistance 0→6
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · France
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Paris216 · +0.42
Toulouse47 · +0.28
Lyon41 · +0.40
Marseille39 · +0.51
Grenoble20 · +0.56
Strasbourg14 · +0.54
PATENT SIGNAL · France
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
34,222 filings8,000 assigneespeak 3751/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Centre NAT RECH Scient10049
- INST NAT Sante RECH MED8302
- Sanofi3990
- Pasteur Institut3423
- Agronomique INST NAT RECH1334
- Cellectis1320
- PF Medicament1204
- Commissariat Energie Atomique1153
Common questions
How many Life Sciences companies are there in Auvergne Rhone Alpes, France?
Radar tracks 194 indexable Life Sciences companies headquartered in Auvergne Rhone Alpes, France that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Auvergne Rhone Alpes, France?
The Life Sciences companies in Auvergne Rhone Alpes, France on this list have raised a combined $1.7B in disclosed equity funding across 79 funded companies.
Which is the highest-funded Life Sciences company in Auvergne Rhone Alpes, France?
Amolyt Pharma is the highest-funded Life Sciences company in Auvergne Rhone Alpes, France, with $292.3M in disclosed equity funding.
How many Life Sciences companies in Auvergne Rhone Alpes, France are funded?
79 of the 194 Life Sciences companies in Auvergne Rhone Alpes, France on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Auvergne Rhone Alpes, France?
None of the Life Sciences companies in Auvergne Rhone Alpes, France on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Auvergne Rhone Alpes, France Life Sciences companies?
The most active investors in Auvergne Rhone Alpes, France Life Sciences companies on this list include Bpifrance, Europa, Kreaxi, Sofimac Investment Managers, EIC Fund.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.